<DOC>
	<DOCNO>NCT01116271</DOCNO>
	<brief_summary>The purpose study determine whether treatment Selumetinib ( AZD6244 ) ( Hyd-Sulfate ) combination Irinotecan second treatment patient K-ras B-raf mutation prevent tumor progression prolong progression free survival .</brief_summary>
	<brief_title>Study Selumetinib ( AZD6244 ) ( ARRY-142886 ) Combination With Irinotecan Previously Treated Patients With Colorec</brief_title>
	<detailed_description>A Dose Finding Phase II Study Selumetinib ( AZD6244 ) ( Hyd-Sulfate ) Combination Irinotecan , 2nd Line Patients K-ras B-raf Mutation Positive Advanced Metastatic Colorectal Cancer</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Histological cytological confirmation advance metastatic colorectal cancer available tissue tumor sample confirm Kras Braf mutation positive . Current failure 1st line anticancer therapy oxaliplatin bevacizumab base regimen patient relapse within 12 month complete adjuvant FOLFOX . Treatment within 14 day prior first study treatment conventional therapy treatment within 28 day prior first study treatment investigational drug Prior treatment MEK Braf inhibitor irinotecancontaining regimen Prior treatment MEK Braf inhibitor irinotecancontaining regimen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>colorectal</keyword>
	<keyword>second line therapy</keyword>
	<keyword>K-ras B-raf mutation</keyword>
	<keyword>response rate</keyword>
	<keyword>Progression Free Survival</keyword>
</DOC>